PhRMA's new Scientific Leadership Advisory Council is guiding efforts to integrate science into advocacy. The goal is to shift the culture of PhRMA itself and change the conversation on Capitol Hill.
AstraZeneca's third business development model in four years continues to integrate BD into research, and installs an over-arching structure to orchestrate therapeutic strategies from R&D through commercial.
PRODUCT DISCOVERY & DEVELOPMENT
The Partnership to Accelerate Clinical Trials, backed by Bay Area's BioEconomy Initiative, aims to create a centralized IRB across California.
EMERGING COMPANY PROFILE
Alzheon hopes an improved version of a failed beta amyloid aggregation blocker will treat Alzheimer's in APOE4 carriers.
Armo is developing a pegylated form of IL-10 for cancer based on new evidence the former Merck molecule can stimulate an immune response against tumor cells.
FDA Commissioner Margaret Hamburg says FDA, industry and medical practice must change to adapt to rapidly evolving science.
The ability to create a consolidated cancer immunotherapy powerhouse with a host of clinical programs led Arch and Alaska Permanent Fund to commit $120 million in the largest series A round of the decade.
A task force of bankers, investors and industry players is waiting for SEC to respond to the group's recommendations for improving liquidity and access to capital for small cap companies.
Celgene, Lilly sweeten VC pot for NYC. Editas gets crisp money. MS Ventures plants more seeds in Israel. Sofinnova not blind to Pixium's opportunity. Also: Wetherell-Burrill; AcelRx; Auxilium; Immunocellular; Lexicon; Merrimack; Orexigen; Puma; Receptos; Oncolys; TWi; Xencor, et al.